Literature DB >> 25982918

Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature.

Francesco Dentali1, Matteo Nicola Dario Di Minno, Monica Gianni, Pasquale Ambrosino, Alessandro Squizzato, Walter Ageno.   

Abstract

Limited information exists on the safety and efficacy of non-vitamin K oral anticoagulants (NOACs) in patients with pulmonary embolism (PE). The aim of this study is to evaluate the difference in the safety and efficacy of the NOACs in comparison to the standard treatment in patients presenting with deep vein thrombosis (DVT) and with PE using data from randomized controlled trials. MEDLINE and EMBASE databases were searched. Differences in the efficacy (recurrent VTE or death-related VTE) and in the safety (major bleeding) outcome were expressed as risk ratio (RR) with 95% confidence intervals (95% CI). Heterogeneity among the studies was assessed. Six studies (27,023 patients) were included. NOACs appeared to have a similar efficacy and safety compared to VKAs in patients presenting with PE and with DVT with a non-significant heterogeneity between the groups (efficacy: RR 0.90, 95% CI 0.72, 1.13 in PE patients and 0.93, 95% CI 0.75, 1.16 in DVT patients; χ2 0.04, p = 0.84; safety: RR 0.49, 95% CI 0.26, 0.95 in PE patients and 0.74 95% CI 0.51, 1.06 in DVT; χ2 1.10, p = 0.29). Our results suggest that the efficacy and safety of the NOACs compared to VKAs is similar between patients with PE and DVT.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25982918     DOI: 10.1007/s11739-015-1249-x

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  20 in total

Review 1.  Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis.

Authors:  J A Sterne; M Egger; G D Smith
Journal:  BMJ       Date:  2001-07-14

2.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Authors:  Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

Review 3.  Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review.

Authors:  R D Hull; G F Pineo; P D Stein; A F Mah; S M MacIsaac; O E Dahl; M Butcher; R F Brant; W A Ghali; D Bergqvist; G E Raskob
Journal:  Ann Intern Med       Date:  2001-11-20       Impact factor: 25.391

4.  Efficacy and safety of direct oral anticoagulants after pulmonary embolism: a meta-analysis.

Authors:  Maria Cristina Vedovati; Cecilia Becattini; Federico Germini; Giancarlo Agnelli
Journal:  Int J Cardiol       Date:  2014-08-30       Impact factor: 4.164

Review 5.  Pulmonary embolism and deep vein thrombosis.

Authors:  Samuel Z Goldhaber; Henri Bounameaux
Journal:  Lancet       Date:  2012-04-10       Impact factor: 79.321

6.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

7.  Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry.

Authors:  Silvy Laporte; Patrick Mismetti; Hervé Décousus; Fernando Uresandi; Remedios Otero; Jose Luis Lobo; Manuel Monreal
Journal:  Circulation       Date:  2008-03-17       Impact factor: 29.690

Review 8.  Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.

Authors:  Antonio Gómez-Outes; Ana Isabel Terleira-Fernández; Ramón Lecumberri; M Luisa Suárez-Gea; Emilio Vargas-Castrillón
Journal:  Thromb Res       Date:  2014-07-06       Impact factor: 3.944

9.  Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.

Authors:  Sam Schulman; Ajay K Kakkar; Samuel Z Goldhaber; Sebastian Schellong; Henry Eriksson; Patrick Mismetti; Anita Vedel Christiansen; Jeffrey Friedman; Florence Le Maulf; Nuala Peter; Clive Kearon
Journal:  Circulation       Date:  2013-12-16       Impact factor: 29.690

Review 10.  Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.

Authors:  Saskia Middeldorp; Martin H Prins; Barbara A Hutten
Journal:  Cochrane Database Syst Rev       Date:  2014-08-05
View more
  7 in total

1.  Vitamin K antagonists in the era of direct oral anticoagulants: is there still a room for their use?

Authors:  Francesco Dentali; Silvia Galliazzo; Francesca Zuretti; Monica Gianni
Journal:  Intern Emerg Med       Date:  2017-08-04       Impact factor: 3.397

Review 2.  The 2016 American College of Chest Physicians treatment guidelines for venous thromboembolism: a review and critical appraisal.

Authors:  James Demetrios Douketis
Journal:  Intern Emerg Med       Date:  2016-10-20       Impact factor: 3.397

3.  Claims-based or clinical models for predicting 90-day post-pulmonary embolism outcomes.

Authors:  Cecilia Becattini; Giancarlo Agnelli
Journal:  Intern Emerg Med       Date:  2017-05-22       Impact factor: 3.397

4.  Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.

Authors:  Davide Imberti; Daniela Mastroiacovo
Journal:  Intern Emerg Med       Date:  2017-06-24       Impact factor: 3.397

5.  Prognosis and risk factors in older patients with lung cancer and pulmonary embolism: a propensity score matching analysis.

Authors:  Liu Junjun; Wang Pei; Yan Ying; Song Kui
Journal:  Sci Rep       Date:  2020-01-27       Impact factor: 4.379

6.  American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.

Authors:  Thomas L Ortel; Ignacio Neumann; Walter Ageno; Rebecca Beyth; Nathan P Clark; Adam Cuker; Barbara A Hutten; Michael R Jaff; Veena Manja; Sam Schulman; Caitlin Thurston; Suresh Vedantham; Peter Verhamme; Daniel M Witt; Ivan D Florez; Ariel Izcovich; Robby Nieuwlaat; Stephanie Ross; Holger J Schünemann; Wojtek Wiercioch; Yuan Zhang; Yuqing Zhang
Journal:  Blood Adv       Date:  2020-10-13

Review 7.  Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies.

Authors:  Emanuel Raschi; Matteo Bianchin; Walter Ageno; Roberto De Ponti; Fabrizio De Ponti
Journal:  Drug Saf       Date:  2016-12       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.